new
coronaviru
sever
acut
respiratori
syndrom
coronaviru
sarscov
identifi
etiolog
agent
sever
acut
respiratori
syndrom
given
highli
contagi
acut
natur
diseas
urgent
need
develop
diagnost
assay
detect
sarscov
infect
total
sera
includ
convalesc
patient
seven
pair
two
time
point
infect
analyz
show
immunoreact
toward
nucleocapsid
protein
n
sera
patient
also
show
immunoreact
protein
uniqu
sarscov
addit
convalescentphas
sera
show
immunoreact
spike
protein
analyz
immunofluoresc
method
util
mammalian
cell
stabli
express
howev
sampl
acut
phase
day
onset
ill
react
suggest
antibodi
n
may
appear
earlier
antibodi
altern
could
due
differ
sensit
two
method
immunoreact
recombin
viral
protein
highli
specif
sera
healthi
donor
react
result
suggest
recombin
n
protein
may
use
antigen
develop
serolog
assay
sarscov
recent
sever
acut
respiratori
syndrom
sar
epidem
affect
countri
profoundli
disturb
social
econom
activ
region
well
global
high
mortal
rate
togeth
highli
contagi
acut
natur
diseas
impos
tremend
psycholog
econom
burden
public
singapor
elsewher
reduc
risk
contact
peopl
may
expos
sarscaus
viru
strict
quarantin
order
serv
travel
sarsaffect
countri
direct
contact
sar
patient
temperatur
exceed
earli
diagnos
diseas
earli
phase
infect
could
avoid
unnecessari
quarantin
reduc
stress
concern
help
doctor
decid
appropri
medic
action
andor
treatment
therefor
vital
identifi
sar
patient
earli
possibl
certainti
accuraci
given
effect
antisar
therapeut
current
avail
first
line
defens
identifi
isol
infect
patient
earli
possibl
henc
need
develop
sensit
highli
specif
diagnost
kit
use
field
urgent
immedi
novel
coronaviru
identifi
etiolog
agent
sar
coronavirus
envelop
virus
contain
singlestrand
positivesens
rna
genom
kb
analys
nucleotid
sequenc
novel
sar
coronaviru
sarscov
show
viral
genom
nearli
kb
length
contain
potenti
open
read
frame
orf
identif
sarscov
genom
sever
diagnost
test
base
detect
viral
rna
sequenc
use
pcr
design
avail
test
although
sensit
inher
problem
scientist
clinician
around
world
unsur
type
sampl
respiratori
sampl
saliva
stool
blood
conjunctiv
fluid
patient
give
reproduc
rna
prepar
rna
extract
protocol
straightforward
done
well
may
produc
rna
prepar
use
revers
transcript
step
convert
viral
rna
dna
whole
process
extract
revers
transcript
pcr
timeconsum
confirmatori
test
done
sever
pair
primer
addit
fals
posit
possibl
amplif
method
observ
august
canada
patient
infect
human
coronavirus
initi
test
posit
sar
pcr
method
http
wwwbccdcorg
contamin
pcr
laboratori
alway
concern
case
sar
could
lead
unnecessari
quarantin
anoth
commonli
use
method
detect
viral
infect
serolog
test
assay
presenc
antibodi
viral
protein
sequenc
sarscov
reveal
orf
four
structur
protein
ie
spike
membran
envelop
e
nucleocapsid
n
present
coronavirus
addit
sever
orf
predict
sarscov
sequenc
encod
protein
uniqu
sarscov
show
signific
sequenc
homolog
viral
protein
coronavirus
studi
screen
panel
sarscov
orf
express
mammalian
andor
bacteri
cell
reactiv
toward
convalescentphas
patient
sera
well
sera
acut
infect
patient
determin
antigen
would
suitabl
diagnost
marker
detect
sarscov
infect
reagent
use
studi
purchas
sigma
st
loui
mo
unless
otherwis
state
cell
line
purchas
american
type
cultur
collect
manassa
va
cultur
co
dulbecco
modifi
eagl
medium
contain
g
glucoselit
mm
lglutamin
g
sodium
bicarbonatelit
mm
nonessenti
amino
acid
mg
streptomycinml
u
penicillin
fetal
bovin
serum
hyclon
south
logan
utah
construct
plasmid
transient
express
mammalian
cell
vector
use
tag
protein
n
terminu
one
hemagglutinin
ha
epitop
tag
protein
three
ha
epitop
c
terminu
leung
institut
molecular
cell
biolog
singapor
republ
singapor
person
commun
express
glutathion
stransferas
gst
fusion
protein
bacteria
gene
clone
frame
gst
amersham
pharmacia
biotech
uppsala
sweden
stabl
transfect
cho
cell
fulllength
construct
tag
ctermin
end
green
fluoresc
protein
gfp
clone
pmmtc
vector
construct
use
studi
list
tabl
sarscov
isol
sar
patient
singapor
use
studi
clone
variou
gene
rna
extract
use
qiagen
viral
rna
kit
valencia
calif
sarscovinfect
vero
cell
cultur
supernat
harvest
cultur
show
least
cytopath
effect
revers
transcript
perform
superscript
ii
rnase
h
revers
transcriptas
gibco
brl
gaithersburg
md
oligo
dt
primer
pcr
perform
either
hotstar
polymeras
qiagen
titanium
taq
dna
polymeras
clontech
laboratori
inc
palo
alto
calif
high
fidel
taq
polymeras
roch
molecular
biochem
indianapoli
ind
case
overlap
cdna
provid
genom
institut
singapor
isol
access
use
templat
instead
primer
use
studi
synthes
genset
singapor
biotech
singapor
sequenc
construct
use
studi
confirm
dna
sequenc
perform
core
facil
institut
molecular
cell
biolog
dideoxi
method
taq
dyedeoxi
termin
cycl
sequenc
kit
autom
dna
sequenc
model
pe
appli
biosystem
foster
citi
calif
transient
transfect
mammalian
cell
transient
transfect
experi
perform
effecten
transfect
reagent
qiagen
accord
manufactur
protocol
typic
cell
plate
dish
allow
attach
least
h
one
g
dna
use
per
plate
cell
left
least
h
cell
wash
phosphatebuff
salin
pb
lyse
directli
laemmli
sodium
dodecyl
sulfat
sd
buffer
use
western
blot
analysi
express
gst
fusion
protein
exponenti
grow
cultur
optic
densiti
nm
escherichia
coli
cell
harbor
express
construct
induc
synthes
fusion
protein
addit
mm
iptg
cell
allow
grow
anoth
h
h
cell
harvest
resuspend
pb
contain
triton
mm
phenylmethylsulfonyl
fluorid
sonic
ultrason
processor
misonix
inc
farmingdal
ny
gst
fusion
protein
purifi
lysat
use
glutathion
gsh
sepharos
bead
amersham
pharmacia
biotech
protein
elut
bead
mm
reduc
gsh
mm
trishcl
ph
sd
protein
concentr
determin
use
coomassi
plu
assay
kit
pierc
rockford
ill
protein
also
separ
sdspolyacrylamid
gel
stain
coomassi
brilliant
blue
biorad
hercul
calif
methanol
acet
acid
western
blot
analysi
western
blot
analysi
approxim
transfect
cell
ng
gst
fusion
protein
separ
sdspolyacrylamid
gel
transfer
nitrocellulos
hybond
c
membran
amersham
pharmacia
biotech
membran
block
nonfat
dri
milk
detect
hatag
gst
fusion
protein
membran
incub
either
antiha
polyclon
antigst
monoclon
antibodi
santa
cruz
biotechnolog
santa
cruz
calif
overnight
wash
extens
pbst
pb
contain
tween
follow
incub
appropri
horseradish
peroxidas
hrp
conjug
secondari
antibodi
pierc
h
room
temperatur
membran
wash
extens
pbst
detect
signal
enhanc
chemiluminesc
method
pierc
perform
patient
sera
sampl
first
treat
triton
mg
rnase
sigma
ml
dilut
pbst
contain
nonfat
dri
milk
incub
h
room
temperatur
overnight
membran
incub
antihuman
hrpconjug
immunoglobulin
g
igg
santa
cruz
biochem
iga
igm
zyme
laboratori
inc
san
francisco
calif
antibodi
h
room
temperatur
follow
detect
describ
secondari
antibodi
use
dilut
due
limit
amount
patient
sera
seven
pair
sera
western
blot
mixtur
three
gst
fusion
protein
n
gst
run
singleslot
polyacrylamid
gel
electrophoresi
page
gel
transfer
onto
nitrocellulos
membran
membran
cut
strip
mm
wide
strip
probe
l
dilut
sera
late
time
point
sera
strip
incub
dilut
sera
h
room
temperatur
earli
time
point
sera
strip
incub
overnight
sera
room
temperatur
detect
signal
secondari
antibodi
incub
h
room
temperatur
method
also
use
larg
number
sampl
screen
express
sgfp
fusion
protein
cho
cell
immunofluoresc
analysi
determin
anti
immunoreact
patient
sera
cho
cell
transfect
pmmtcsgfp
use
dmriec
reagent
gibco
brl
accord
manufactur
protocol
transfect
cell
select
geneticin
gibco
brl
week
cell
analyz
zeiss
microscop
carl
zeiss
vision
gmbh
hallbergmoss
germani
clone
strongest
express
signal
pick
grown
medium
contain
znso
zn
ion
increas
express
gene
pmmtc
vector
cell
dislodg
plate
edta
seed
onto
black
teflon
menzel
diagnost
slide
merck
blown
dri
follow
fix
aceton
h
cell
incub
sera
dilut
pb
h
follow
incub
fluorescein
isothiocyan
fitc
rhodamin
rh
conjug
antihuman
igg
sigma
dilut
h
rhconjug
antihuman
igg
use
dilut
pb
fitcconjug
antihuman
igg
igm
sigma
iga
dako
glostrup
denmark
use
dilut
evan
blue
solut
fluka
buch
switerland
block
gfp
fluoresc
transfect
cell
slide
view
zeiss
microscop
carl
zeiss
vision
gmbh
score
follow
strong
stain
moder
stain
weak
stain
collect
sera
sarscovinfect
patient
first
six
serum
sampl
patient
except
patient
obtain
second
set
sera
consist
seven
pair
sampl
collect
patient
admit
tan
tock
seng
hospit
singapor
gener
hospit
patient
admit
upon
onset
ill
defin
criteria
date
admiss
date
collect
blood
shown
tabl
first
sampl
set
collect
day
onset
ill
second
set
sampl
set
b
collect
day
onset
ill
last
set
sera
obtain
probabl
sar
patient
discharg
tan
tock
seng
hospit
patient
sera
taken
upon
discharg
week
onset
ill
patient
recruit
week
discharg
week
onset
ill
see
tabl
detail
one
patient
patient
serum
sampl
taken
day
month
onset
ill
sampl
two
patient
obtain
plasmapheresi
control
serum
purchas
sigma
serum
sampl
obtain
healthi
donor
given
inform
consent
healthi
donor
diagnosi
sar
suspect
sar
contact
person
serv
home
quarantin
order
sar
ii
fever
symptom
influenza
runni
nose
sore
throat
within
last
week
time
donat
iii
immunosuppress
iv
signific
medic
ill
v
histori
travel
sarsaffect
area
sinc
novemb
order
assess
viral
protein
encod
sarscov
genom
may
exploit
diagnost
antigen
develop
serolog
assay
detect
sarscov
infect
clone
three
four
structur
protein
e
n
express
vector
due
larg
size
kbp
heavi
glycosyl
spike
protein
analyz
separ
immunofluoresc
method
see
addit
two
sarscov
uniqu
protein
also
includ
studi
refer
hereaft
ux
x
stand
number
predict
amino
acid
protein
studi
use
ctermin
hydrophil
region
three
potenti
transmembran
domain
ntermin
end
hydrophob
region
may
affect
solubl
recombin
protein
posit
structur
uniqu
protein
correspond
orf
number
design
marra
cowork
shown
fig
panel
hatag
protein
express
cell
transient
transfect
total
protein
lysat
analyz
western
blot
analysi
sera
three
convalesc
patient
fig
patient
determin
sera
antibodi
express
protein
plasmapheresi
perform
patient
plasmapheresi
product
use
western
blot
analysi
patient
serum
use
analysi
three
patient
antibodi
n
amino
acid
aa
protein
structur
protein
e
interestingli
ctermin
hydrophil
region
aa
also
detect
sera
patient
serum
patient
fig
control
serum
detect
n
protein
also
detect
three
sera
suggest
may
express
structur
protein
suffici
antigen
bacteri
express
protein
easier
cheaper
produc
larg
scale
next
express
n
gst
fusion
protein
test
reactiv
patient
sera
coomassi
stain
show
gstn
aa
aa
puriti
onestep
purif
gshsepharos
bead
fig
gstn
aa
protein
use
lack
ntermin
part
n
protein
contain
highli
conserv
motif
fyylgtgp
aa
sarscov
n
found
coronavirus
would
less
chanc
crossreact
antibodi
coronavirus
bacteri
cultur
mg
gstn
mg
could
obtain
respect
aa
lack
signal
peptid
n
terminu
hydrophob
c
terminu
gst
also
express
use
control
gst
fusion
protein
probe
three
patient
sera
one
control
serum
mammalian
express
protein
fig
consist
protein
express
cell
gstn
clearli
detect
three
patient
sera
detect
sera
patient
fig
neither
gst
show
background
three
patient
sera
nonspecif
bind
control
serum
protein
fig
sera
anoth
three
convalesc
patient
patient
also
test
reactiv
specif
toward
gstn
gst
fig
profil
igg
igm
iga
antibodi
n
protein
seven
pair
sera
obtain
two
time
point
infect
set
pair
sera
seven
patient
also
examin
reactiv
gstn
obtain
two
time
point
infect
one
day
onset
ill
set
anoth
day
onset
ill
set
b
tabl
seven
case
second
time
point
sampl
taken
least
day
first
time
point
sampl
shown
fig
antiigg
antibodi
gstn
protein
present
seven
patient
sera
later
time
point
set
b
earli
time
point
set
set
sera
membran
incub
dilut
sera
h
room
temperatur
follow
incub
secondari
anti
bodi
hrpconjug
antihuman
igg
h
room
temperatur
addit
seven
late
time
point
sera
also
contain
antibodi
albeit
lower
level
gstn
fig
set
b
repeat
experi
earli
time
point
sera
set
incub
blot
dilut
sera
overnight
room
temperatur
instead
h
use
three
differ
secondari
antibodi
antiigg
antiigm
antiiga
result
shown
fig
igg
sampl
show
reactiv
gstn
iga
though
seven
sampl
show
reactiv
gstn
signal
particularli
strong
sampl
igm
seven
sampl
show
low
level
reactiv
gstn
earli
time
point
sampl
patient
collect
differ
number
day
onset
ill
result
suggest
earli
day
onset
ill
patient
sampl
igm
iga
antibodi
n
protein
present
day
onset
ill
high
level
iga
antibodi
n
present
igm
igg
antibodi
also
detect
fig
sampl
reactiv
observ
iga
sampl
igm
sampl
day
onset
ill
interestingli
quit
strong
signal
observ
sampl
day
onset
ill
igm
use
correspond
earli
sampl
signal
also
strong
fig
determin
sensit
specif
immunoreact
igg
n
protein
order
determin
sensit
specif
immunoreactiv
determin
western
blot
analysi
strong
moder
weak
signal
respect
observ
autoradiograph
signal
observ
b
determin
immunofluoresc
method
cho
cell
stabli
express
protein
incub
dilut
patient
serum
follow
fitcconjug
antihuman
igg
antibodi
slide
view
zeiss
microscop
score
follow
strong
stain
moder
stain
weak
stain
one
hundr
sera
healthi
volunt
examin
dilut
none
show
stain
c
sampl
obtain
state
number
day
onset
ill
sampl
two
healthi
contact
patient
also
examin
e
sampl
obtain
plasmapheresi
f
late
time
point
one
seven
pair
sera
describ
tabl
iti
n
obtain
anoth
sampl
probabl
sar
patient
discharg
hospit
test
presenc
igg
antibodi
n
western
blot
analysi
shown
tabl
sampl
taken
day
onset
ill
plasmapheresi
product
patient
sera
patient
use
sampl
show
strong
immunoreact
n
protein
sampl
posit
tabl
gener
signal
observ
protein
much
lower
n
protein
except
sampl
patient
signal
n
protein
equal
strong
anoth
sampl
healthi
donor
also
test
none
show
immunoreact
n
addit
sampl
two
patient
patient
close
contact
probabl
sar
patient
never
develop
clinic
symptom
also
show
immunoreact
n
tabl
therefor
immunoreact
n
protein
highli
sensit
found
total
sampl
probabl
sar
patient
specif
detect
igg
antibodi
sarscov
protein
convalescentphas
sera
immunofluoresc
due
larg
size
heavi
glycosyl
protein
advantag
express
protein
mammalian
cell
instead
bacteria
possibl
detect
antibodi
may
depend
conform
andor
glycosyl
protein
cho
cell
stabli
transfect
fulllength
construct
tag
ctermin
end
gfp
select
antibiot
pool
clone
express
signific
level
protein
indic
gfp
fluoresc
obtain
fig
cho
cell
use
immunofluoresc
stain
method
determin
igg
antibodi
sarscov
protein
convalescentphas
sera
briefli
cell
fix
aceton
incub
dilut
patient
sera
follow
incub
rhconjug
antihuman
igg
antibodi
shown
fig
sera
patient
contain
igg
antibodi
detect
immunofluoresc
signal
observ
control
serum
use
remain
sampl
test
similarli
except
rhconjug
antihuman
igg
antibodi
replac
fitcconjug
one
presenc
high
concentr
evan
blue
solut
greater
eas
judg
cell
stain
fitc
stain
rh
concentr
evan
blue
solut
suffici
block
gfp
fluoresc
transfect
cell
data
shown
shown
tabl
convalescentphas
sera
sampl
show
immunoreact
dilut
sampl
healthi
donor
show
signal
dilut
lowest
march
guest
http
cviasmorg
dilut
test
sampl
healthi
donor
show
weak
signal
concentr
therefor
result
dilut
use
comparison
higher
dilut
weaker
signal
observ
patient
sera
would
expect
particular
sampl
strong
signal
observ
dilut
signal
decreas
gradual
higher
dilut
ie
moder
signal
observ
weak
signal
observ
seven
earli
time
point
sampl
tabl
set
also
analyz
manner
igg
igm
iga
secondari
antibodi
separ
none
show
reactiv
dilut
data
shown
sequenc
sarscov
reveal
orf
four
structur
protein
ie
e
n
present
coronavirus
protein
play
essenti
role
mediat
receptor
bind
intern
viru
one
major
antigen
viru
e
protein
essenti
virion
assembl
n
protein
bind
viral
genom
form
nucleocapsid
besid
four
common
structur
protein
sever
uniqu
orf
predict
sarscov
sequenc
whether
orf
express
whether
express
protein
serv
function
viral
replic
cycl
yet
determin
first
screen
panel
orf
express
mammalian
bacteri
cell
reactiv
toward
convalescentphas
patient
sera
shown
fig
n
protein
found
strong
immunoreact
igg
six
convalescentphas
sera
test
test
use
seven
pair
fig
detect
n
sera
patient
earli
late
phase
infect
reactiv
gstn
determin
sera
seven
pair
sampl
set
repres
sampl
earli
time
point
day
onset
ill
set
b
repres
sampl
collect
later
time
point
day
onset
ill
gst
fusion
protein
transfer
nitrocellulos
membran
membran
incub
dilut
sera
h
room
temperatur
follow
incub
hrpconjug
antihuman
igg
secondari
antibodi
h
room
temperatur
b
sampl
set
reexamin
use
three
differ
secondari
antibodi
name
antihuman
igg
antihuman
iga
antihuman
igm
antibodi
membran
incub
dilut
sera
overnight
room
temperatur
follow
incub
respect
secondari
antibodi
h
room
temperatur
tan
et
al
clin
diagn
lab
immunol
fig
detect
anti
antibodi
patient
sera
immunofluoresc
method
util
mammalian
cell
stabli
express
protein
pool
cho
cell
stabli
transfect
fulllength
construct
tag
ctermin
end
gfp
show
gfp
fluoresc
gfp
panel
cell
fix
incub
control
patient
sera
dilut
follow
rhconjug
antihuman
igg
antibodi
cell
incub
patient
sera
patient
show
strong
stain
stain
seen
control
serum
use
vol
antibodi
respons
sar
viral
protein
march
guest
http
cviasmorg
sera
patient
also
show
high
level
igg
antibodi
n
protein
present
later
time
point
day
tabl
sampl
fig
set
b
earli
time
point
set
lower
level
igg
igm
antibodi
n
two
patient
iga
antibodi
n
present
high
level
fig
sampl
earli
time
point
serum
patient
sampl
taken
day
onset
ill
data
suggest
high
level
iga
antibodi
n
present
time
taken
togeth
seven
earli
sampl
set
show
immunoreact
n
protein
one
sampl
taken
earli
day
onset
ill
sampl
final
third
set
sampl
convalesc
patient
posit
igg
antibodi
n
tabl
sampl
collect
day
onset
ill
high
level
igg
antibodi
n
observ
consist
recent
report
igg
antibodi
sarscov
patient
persist
week
onset
symptom
presenc
strong
immunoreact
toward
n
suggest
may
releas
viru
infect
cell
circul
stage
infect
may
present
antigenpres
cell
cytotox
kill
infect
cell
therefor
specul
igg
antibodi
n
may
contribut
humor
immun
respons
protect
patient
sar
observ
coronavirus
futur
experi
aim
address
mechan
n
present
antigen
role
viral
infect
andor
replic
result
also
complement
preliminari
mass
spectrometr
identif
n
immunogen
viral
antigen
interestingli
unlik
coronavirus
protein
abund
n
appear
abund
protein
sarscov
may
expect
convalescentphas
sera
also
show
reactiv
larg
glycoprotein
respons
petalshap
spike
found
surfac
coronavirus
case
use
fulllength
express
mammalian
cell
cho
achiev
proper
fold
glycosyl
protein
immunofluoresc
techniqu
analysi
advantag
immunofluoresc
use
sarscovinfect
vero
cell
latter
would
requir
biosafeti
level
facil
howev
method
still
need
special
expertis
laborintens
thu
suit
mass
test
therefor
futur
studi
import
determin
epitop
protein
recogn
antibodi
patient
sera
epitop
may
easier
express
fulllength
protein
may
allow
develop
chromatograph
enzymelink
immunosorb
assay
elisa
base
diagnost
assay
addit
also
found
major
patient
antibodi
ctermin
end
correspond
orf
annot
refer
refer
protein
uniqu
sarscov
immunoreact
indic
novel
uniqu
viral
protein
express
like
protein
involv
biogenesi
sarscov
moreov
potenti
transcript
regul
sequenc
found
upstream
code
sequenc
suggest
first
orf
one
major
subgenom
rna
sarscovinfect
cell
share
signific
homolog
protein
databas
appear
similar
topolog
three
transmembran
region
larg
intern
ctermin
domain
would
interest
unravel
function
patient
studi
show
differenti
respons
n
import
determin
futur
studi
differ
correl
signific
clinic
paramet
identif
n
antigen
protein
diagnost
test
develop
detect
presenc
antibodi
protein
suspect
patient
fact
earlyphas
sera
seven
patient
show
immunoreact
n
iga
andor
igm
offer
power
reliabl
system
diagnosi
earli
infect
addit
presenc
high
level
igg
antibodi
protein
particular
n
protein
late
infect
convalescentphas
sera
suggest
system
would
also
suitabl
epidemiolog
studi
studi
sequenti
bled
patient
earli
stage
infect
need
character
develop
antibodi
time
consequ
util
earli
infect
n
protein
easili
express
bacteria
may
purifi
high
degre
might
provid
better
sensit
specif
current
use
coars
viral
lysat
serolog
assay
presenc
antibodi
cellular
compon
viral
lysat
result
fals
posit
therefor
use
recombin
viral
antigen
rapid
chromatograph
elisabas
kit
expect
yield
superior
diagnost
test
due
difficulti
express
protein
n
protein
appear
best
candid
develop
serolog
assay
rapid
detect
sarscov
infect
inde
recombin
protein
describ
shown
work
well
elisa
format
still
clear
whether
sarscov
undergo
high
rate
genet
mutat
although
differ
observ
viral
genom
sequenc
far
exampl
see
refer
howev
protein
predict
contain
hypervari
region
found
coronavirus
might
pose
anoth
problem
use
diagnost
assay
n
protein
compar
sequenc
sar
isol
deposit
genbank
databas
found
two
show
differ
one
amino
acid
singapor
isol
use
studi
data
shown
also
see
refer
therefor
n
protein
appear
undergo
rapid
mutat
anoth
advantag
use
serolog
assay
develop
slightli
larger
varianc
differ
report
sequenc
five
sequenc
show
one
amino
acid
substitut
compar
one
sequenc
show
two
amino
acid
substitut
may
one
reason
fewer
patient
sera
compar
n
protein
react
recombin
protein
use
studi
first
dissect
rang
antibodi
respons
sarscov
infect
summari
shown
antibodi
n
protein
present
convalescentphas
sera
patient
fulfil
case
definit
probabl
sar
sera
healthi
contact
volunt
observ
consist
find
sarscov
caus
agent
sar
analysi
seven
pair
sera
show
lower
level
antibodi
mainli
igm
iga
n
present
acut
phase
infect
high
level
igg
antibodi
detect
day
date
serolog
diagnosi
sar
reliabl
method
requir
convalescentphas
serum
collect
day
onset
ill
accur
http
wwwcdcgovncidodsarstestresultschtm
thu
retrospect
data
show
igm
andor
iga
assay
could
help
earli
diagnosi
although
li
cowork
report
patient
posit
igm
week
ill
assay
coars
viral
lysat
use
recombin
n
protein
may
increas
sensit
elisa
assay
allow
earlier
detect
